Adamas Pharmaceuticals Inc: management transactions · United States · SEC (Form 4)

About Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc. was a U.S.-based specialty pharmaceutical company historically listed on the NASDAQ under the ticker ADMS before its acquisition by Supernus Pharmaceuticals, which was completed in November 2021. For French, Belgian, and Swiss investors, this is an important distinction: Adamas no longer trades as an independent public company, but its legacy remains relevant for SEC filings, including Form 4 insider transaction analysis and governance review. The company was founded in Emeryville, California, and built its strategy around chronic neurological disorders, with a clear focus on central nervous system (CNS) diseases. Adamas positioned itself as a developer and commercializer of chrono-synchronous therapies designed to improve day-to-day functioning for patients living with disabling neurologic conditions. In practical terms, its business model was centered on high-value, specialty neurologic medicines rather than broad primary-care franchises. Adamas’ commercial profile was anchored by two marketed products. GOCOVRI, an extended-release formulation of amantadine, was described as the first and only FDA-approved medicine indicated for both “OFF” episodes and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. OSMOLEX ER, another amantadine extended-release product, was approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adults. These products formed the core of Adamas’ revenue-generating platform in the United States, which was the company’s key market. From a competitive standpoint, Adamas occupied a specialized niche rather than a large-scale diversified pharmaceutical position. Its differentiation came from the clinical and regulatory profile of GOCOVRI in Parkinson’s disease, especially the combination of dyskinesia and OFF-episode utility, which created a more defensible therapeutic story than a commodity generics model. That said, the company’s narrow product base also meant limited diversification, making execution and reimbursement dynamics especially important. Recent major developments were dominated by the strategic acquisition by Supernus Pharmaceuticals. Supernus announced the deal in October 2021 and completed it in November 2021, bringing Adamas’ Parkinson’s-focused portfolio into a larger CNS platform. As a result, Adamas ceased to exist as an independent listed company on the NASDAQ market in the United States. For investors, that means any current references to ADMS are best understood in a historical and transactional context, particularly when reviewing legacy insider activity, filing history, and the evolution of the company’s asset base prior to integration.